Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376643595> ?p ?o ?g. }
- W4376643595 endingPage "3248" @default.
- W4376643595 startingPage "3241" @default.
- W4376643595 abstract "Galectin-3 binding protein (Gal-3BP) is a glycoprotein that is overexpressed and secreted by several cancers and has been implicated as a marker of both tumor progression and poor prognosis in melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and breast cancer. The expression of Gal-3BP by a variety of neoplasms makes it an enticing target for both diagnostics and therapeutics, including immuno-positron emission tomography (immunoPET) probes and antibody-drug conjugates (ADCs). Herein, we report the development, in vitro characterization, and in vivo evaluation of a pair of Gal-3BP-targeting radioimmunoconjugates for 89Zr-immunoPET. A humanized anti-Gal-3BP antibody, 1959, and its corresponding ADC, 1959-sss/DM4 (DM4 = ravtansine), were modified with desferrioxamine (DFO) to yield DFO-1959 and DFO-1959-sss/DM4 immunoconjugates bearing 1–2 DFO/monoclonal antibody. Both DFO-modified immunoconjugates retained their affinity for Gal-3BP in enzyme-linked immunosorbent assay experiments. The chelator-bearing antibodies were radiolabeled with zirconium-89 (t1/2 ≈ 3.3 d) to produce radioimmunoconjugates ─ [89Zr]Zr-DFO-1959 and [89Zr]Zr-DFO-1959-sss/DM4 ─ with high specific activity (>444 MBq/mg, >12 mCi/mg) and stability (>80% intact after 168 h in human serum at 37 °C). In mice bearing subcutaneous Gal-3BP-secreting A375-MA1 xenografts, [89Zr]Zr-DFO-1959 clearly delineated tumor tissue, reaching a maximum tumoral activity concentration (54.8 ± 15.8%ID/g) and tumor-to-background contrast (tumor-to-blood = 8.0 ± 4.6) at 120 h post-injection. The administration of [89Zr]Zr-DFO-1959 to mice bearing subcutaneous Gal-3BP-expressing melanoma patient-derived xenografts produced similarly promising results. [89Zr]Zr-DFO-1959 and [89Zr]Zr-DFO-1959-sss/DM4 exhibited nearly identical pharmacokinetic profiles in the mice bearing A375-MA1 tumors, though the latter produced higher uptake in the spleen and kidneys. Both [89Zr]Zr-DFO-1959 and [89Zr]Zr-DFO-1959-sss/DM4 effectively visualized Gal-3BP-secreting tumors in murine models of melanoma. These results suggest that both probes could play a role in the clinical imaging of Gal-3BP-expressing malignancies, particularly as companion theranostics for the identification of patients likely to respond to Gal-3BP-targeted therapeutics such as 1959-sss/DM4." @default.
- W4376643595 created "2023-05-17" @default.
- W4376643595 creator A5001857244 @default.
- W4376643595 creator A5011112591 @default.
- W4376643595 creator A5044515513 @default.
- W4376643595 creator A5046997933 @default.
- W4376643595 creator A5056870560 @default.
- W4376643595 creator A5059090988 @default.
- W4376643595 creator A5066000438 @default.
- W4376643595 creator A5080313644 @default.
- W4376643595 creator A5084837942 @default.
- W4376643595 creator A5085796087 @default.
- W4376643595 creator A5091955192 @default.
- W4376643595 date "2023-05-16" @default.
- W4376643595 modified "2023-10-14" @default.
- W4376643595 title "Visualizing Galectin-3 Binding Protein Expression with ImmunoPET" @default.
- W4376643595 cites W1529251418 @default.
- W4376643595 cites W1561727589 @default.
- W4376643595 cites W2033201741 @default.
- W4376643595 cites W2052394530 @default.
- W4376643595 cites W2061352584 @default.
- W4376643595 cites W2082612859 @default.
- W4376643595 cites W2114390384 @default.
- W4376643595 cites W2124532648 @default.
- W4376643595 cites W2130446505 @default.
- W4376643595 cites W2155323332 @default.
- W4376643595 cites W2161075346 @default.
- W4376643595 cites W2198899045 @default.
- W4376643595 cites W2259849752 @default.
- W4376643595 cites W2464480554 @default.
- W4376643595 cites W2560343059 @default.
- W4376643595 cites W2617304390 @default.
- W4376643595 cites W2750969044 @default.
- W4376643595 cites W2784527252 @default.
- W4376643595 cites W2790096396 @default.
- W4376643595 cites W2806009225 @default.
- W4376643595 cites W2810295565 @default.
- W4376643595 cites W2904000890 @default.
- W4376643595 cites W2905720180 @default.
- W4376643595 cites W2921320974 @default.
- W4376643595 cites W2921945710 @default.
- W4376643595 cites W2946962120 @default.
- W4376643595 cites W2959208978 @default.
- W4376643595 cites W2973537060 @default.
- W4376643595 cites W2982411421 @default.
- W4376643595 cites W3021957536 @default.
- W4376643595 cites W3093454786 @default.
- W4376643595 cites W3110336955 @default.
- W4376643595 cites W3202521231 @default.
- W4376643595 cites W3204247219 @default.
- W4376643595 cites W4200015523 @default.
- W4376643595 doi "https://doi.org/10.1021/acs.molpharmaceut.3c00241" @default.
- W4376643595 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37191353" @default.
- W4376643595 hasPublicationYear "2023" @default.
- W4376643595 type Work @default.
- W4376643595 citedByCount "2" @default.
- W4376643595 countsByYear W43766435952023 @default.
- W4376643595 crossrefType "journal-article" @default.
- W4376643595 hasAuthorship W4376643595A5001857244 @default.
- W4376643595 hasAuthorship W4376643595A5011112591 @default.
- W4376643595 hasAuthorship W4376643595A5044515513 @default.
- W4376643595 hasAuthorship W4376643595A5046997933 @default.
- W4376643595 hasAuthorship W4376643595A5056870560 @default.
- W4376643595 hasAuthorship W4376643595A5059090988 @default.
- W4376643595 hasAuthorship W4376643595A5066000438 @default.
- W4376643595 hasAuthorship W4376643595A5080313644 @default.
- W4376643595 hasAuthorship W4376643595A5084837942 @default.
- W4376643595 hasAuthorship W4376643595A5085796087 @default.
- W4376643595 hasAuthorship W4376643595A5091955192 @default.
- W4376643595 hasBestOaLocation W43766435951 @default.
- W4376643595 hasConcept C121608353 @default.
- W4376643595 hasConcept C126322002 @default.
- W4376643595 hasConcept C150903083 @default.
- W4376643595 hasConcept C159654299 @default.
- W4376643595 hasConcept C185592680 @default.
- W4376643595 hasConcept C202751555 @default.
- W4376643595 hasConcept C203014093 @default.
- W4376643595 hasConcept C207001950 @default.
- W4376643595 hasConcept C2776539811 @default.
- W4376643595 hasConcept C2777807558 @default.
- W4376643595 hasConcept C2778019345 @default.
- W4376643595 hasConcept C2778556491 @default.
- W4376643595 hasConcept C2778695046 @default.
- W4376643595 hasConcept C502942594 @default.
- W4376643595 hasConcept C542903549 @default.
- W4376643595 hasConcept C55493867 @default.
- W4376643595 hasConcept C71924100 @default.
- W4376643595 hasConcept C86803240 @default.
- W4376643595 hasConceptScore W4376643595C121608353 @default.
- W4376643595 hasConceptScore W4376643595C126322002 @default.
- W4376643595 hasConceptScore W4376643595C150903083 @default.
- W4376643595 hasConceptScore W4376643595C159654299 @default.
- W4376643595 hasConceptScore W4376643595C185592680 @default.
- W4376643595 hasConceptScore W4376643595C202751555 @default.
- W4376643595 hasConceptScore W4376643595C203014093 @default.
- W4376643595 hasConceptScore W4376643595C207001950 @default.
- W4376643595 hasConceptScore W4376643595C2776539811 @default.
- W4376643595 hasConceptScore W4376643595C2777807558 @default.